Pixofisiran is under clinical development by Sirnaomics and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase II drugs for Basal Cell Carcinoma (Basal Cell Epithelioma) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pixofisiran’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pixofisiran overview

STP705 is under development for the treatment of cutaneous squamous cell carcinoma in situ (isSCC, Bowen's disease), facial squamous cell skin cancer in situ (isSCC), advanced liver tumor, pancreatic cancer, hepatocellular cancer, bladder cancer, basal cell carcinoma, primary sclerosing cholangitis, keloid scarless healing, skin hypertrophic scars, non-alcoholic steatohepatitis, abdominal obesity, cholangiocarcinoma and liver metastasis. The drug is administered topically as cream, through intradermal injection and intra-tumorally and subcutaneously. It is developed based on RNAi technology. It was under development for the treatment of pulmonary fibrosis,kidney fibrosis and wounds.

Sirnaomics overview

Sirnaomics, is a healthcare service provider that discovers and develops therapeutics. The company’s products portfolio includes siRNA and niRNA. It offers product development, preclinical programs, clinical development services, and others. Sirnaomics provides its products for therapeutic programs such as lung cancer, breast cancer, organ transplantation, skin hypertrophic scars, colorectal cancer, influenza A, HPV and cervical cancer, ocular neo-vascularization, spinal cord injury, EBOLA infection, and giloblastoma, among others. The company also provides active pharmaceutical ingredients as therapeutic agents for treatment of various critical human diseases. It has its presence in the US and China. the company is headquartered in Gaithersburg, Maryland, the US.

For a complete picture of Pixofisiran’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.